Mometasona Furoato Kern Pharma (Mometasone Furoate)

Mometasone furoate works by binding to glucocorticoid receptors inside nasal mucosal cells. This complex alters gene transcription, suppressing the release of inflammatory mediators such as cytokines and prostaglandins, which reduces swelling, mucus production, and immune cell activity in the nasal passages.

The appropriate dose is determined by the prescribing healthcare professional based on the patient’s age, condition severity, and response to therapy. Typical regimens involve one or two sprays per nostril once daily, but exact instructions should always follow the prescriber’s order.

Safety data for mometasone furoate in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss use with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Mometasone furoate is a high‑potency intranasal corticosteroid with a low systemic bioavailability, offering effective symptom control at once‑daily dosing. Compared with alternatives such as fluticasone propionate, mometasone often provides comparable efficacy with a similar safety profile, though individual response and tolerability may vary.

Store the nasal spray at room temperature, preferably below 25 °C (77 °F). Keep it in the original packaging to protect from moisture and direct sunlight. Do not freeze the product, and ensure the cap is tightly closed when not in use.

The spray is intended for intranasal use. Gently blow the nose, tilt the head slightly forward, insert the nozzle into one nostril, and press the pump while breathing in gently through the nose. Repeat in the other nostril if prescribed, and avoid blowing the nose immediately after dosing.

Serious risks, though rare, include nasal fungal infections, adrenal suppression with prolonged high‑dose use, severe or persistent nosebleeds, vision changes such as cataracts or glaucoma, and systemic allergic reactions including anaphylaxis. Patients should seek medical attention if any of these occur.

The spray should be avoided in individuals with known hypersensitivity to mometasone furoate or any component of the formulation. It is also contraindicated in patients with active untreated fungal, viral, or bacterial infections of the nasal passages, and in children under the age recommended by the prescriber.